Bictegravir concentrations in breastmilk of healthy, lactating women without HIV.

ABSTRACT:

Introduction

Risk of transmission of HIV through breastfeeding is minimal in case of maternal viral suppression due to antiretroviral therapy. However, to what extent antiretroviral drugs transfer into breastmilk is not fully understood. Data are especially lacking for relatively newer drugs-such as bictegravir-that only recently was approved to use in pregnancy. Therefore, the aim of this study is to determine infant exposure to bictegravir through breastmilk.

Materials and methods

Concentrations of bictegravir were measured in plasma and breastmilk of healthy, lactating women without HIV after a single dose of bictegravir 50 mg (co-formulated with tenofovir alafenamide 25 mg and emtricitabine 200 mg). Concentrations were measured using validated LC-MS/MS assays and pharmac

SUBMITTER: van der Wekken-Pas LC 

PROVIDER: S-EPMC12863268 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature